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Abstract 
Background: We intended to analyse the associations between blood glucose (BG) level and clinical outcomes of 
in‑hospital cardiac arrest (IHCA).
Methods: We conducted a retrospective observational study in a single medical centre and evaluated patients who 
experienced IHCA between 2006 and 2014. We used multivariable logistic regression analysis to study associations 
between independent variables and outcomes. We calculated the mean BG level for each patient by averaging the 
maximum and minimum BG levels in the first 24 h after arrest, and we used mean BG level for our final analysis.
Results: We included a total of 402 patients. Of these, 157 patients (39.1 %) had diabetes mellitus (DM). The aver‑
age mean BG level was 209.9 mg/dL (11.7 mmol/L). For DM patients, a mean BG level between 183 and 307 mg/dL 
(10.2–17.1 mmol/L) was significantly associated with favourable neurological outcome (odds ratio [OR] 2.71, 95 % 
confidence interval [CI] 1.18–6.20; p value = 0.02); a mean BG level between 147 and 317 mg/dL (8.2–17.6 mmol/L) 
was significantly associated with survival to hospital discharge (OR 2.38, 95 % CI 1.26–4.53; p value = 0.008). For 
non‑DM patients, a mean BG level between 143 and 268 mg/dL (7.9–14.9 mmol/L) was significantly associated with 
survival to hospital discharge (OR 2.93, 95 % CI 1.62–5.40; p value < 0.001).
Conclusions: Mean BG level in the first 24 h after cardiac arrest was associated with neurological outcome for IHCA 
patients with DM. For neurological and survival outcomes, the optimal BG range may be higher for patients with DM 
than for patients without DM.
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Background
In the United States, approximately 209,000 patients 
experience in-hospital cardiac arrest (IHCA) each year 
[1]. Despite ongoing efforts to improve the quality of car-
diopulmonary resuscitation (CPR), outcomes following 
IHCA remain poor. Only 20 % of IHCA patients survive 
to hospital discharge, and, if patients survive, as many as 
28 % suffer from significant neurological disability [2].
Dysregulated glucose homeostasis following CPR is 
common [3]. Studies have shown that high blood glu-
cose (BG) levels after return of spontaneous circulation 
(ROSC) are associated with increased mortality and 
poor neurological outcome for patients who experience 
out-of-hospital cardiac arrest (OHCA) [4–7]. For IHCA 
patients, Beiser et  al. reported that for patients without 
diabetes mellitus (DM), both hypoglycaemia and hyper-
glycaemia were associated with decreased survival odds; 
however, for patients with DM, there was little associa-
tion between BG level and survival, except with extreme 
hyperglycaemia [8]. Associations between BG level and 
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The American Heart Association (AHA) guidelines 
[9] do not recommend a target BG range for post-ROSC 
patients; the European Resuscitation Council (ERC) 
guidelines [10] suggest that the BG level be maintained 
below 180 mg/dL (10 mmol/L) in these patients and that 
hypoglycaemia should be avoided. Although the harmful 
effects of hypoglycaemia on survival [11] and neurologi-
cal recovery [12] are well established, the BG level above 
which hyperglycaemia would worsen neurological out-
come is unknown.
The brain is an obligate glucose consumer, so strict 
glucose control might restrict the supply of glucose to 
brain tissue and, hence, worsen brain injury. Oksanen 
et  al. [13] conducted the only randomized controlled 
trial that compared strict BG control (target 72–108 mg/
dL [4–6  mmol/L]) and moderate control (target 108–
144  mg/dL [6–8  mmol/L]) in OHCA patients treated 
with therapeutic hypothermia. They reported that sur-
vival rates did not differ significantly between the two 
treatment groups; furthermore, they noted that levels of 
S-NSE, a surrogate marker for brain injury, increased in 
the strict BG control group [13].
In the current study, we intended to analyse the associ-
ations between BG level and clinical outcomes of IHCA, 
especially neurological outcome. Since the presence of 
DM may modify the body’s physiologic response to BG 
level [8, 14], we also attempted to identify the optimal BG 
levels for IHCA patients with and without DM.
Methods
Setting
We performed this retrospective cohort study at National 
Taiwan University Hospital (NTUH), which is a tertiary 
medical centre with 2600 beds, including 220 beds in 
intensive care units (ICUs). This study was conducted 
in accordance with the amended Declaration of Hel-
sinki. Before data collection, the Research Ethics Com-
mittee of NTUH approved this study and waived the 
requirement for informed consent (Reference number: 
201601047RINB).
According to hospital policy, a code team is activated 
when cardiac arrest events occur on the general wards. 
A code team consists of a senior resident, several jun-
ior residents, a respiratory therapist, a head nurse, and 
several registered ICU nurses. Each code team member 
is certified to provide advanced cardiac life support and 
is capable of offering CPR according to current resus-
citation guidelines. When cardiac arrest events occur 
in the ICUs, a code team is not mobilized since a suffi-
cient number of experienced staff is always present in the 
ICUs. In this case, resuscitation is performed by the staff 
of the ICU where the cardiac arrest event occurs and staff 
from neighbouring ICUs.
Participants
We screened patients who suffered IHCA at NTUH 
between 2006 and 2014. We included patients who met 
the following criteria: (1) age 18 years or older, (2) doc-
umented absence of pulse with performance of chest 
compression for at least 2 min, (3) no documentation of 
a do-not-resuscitate order, and (4) achievement of sus-
tained ROSC (i.e., ROSC ≥  20 min without resumption 
of chest compression). If multiple cardiac arrest events 
occurred in a single patient, only the first event of the 
same hospitalization was recorded. We excluded patients 
without any measurements of BG level within the first 
24  h after sustained ROSC. We also excluded patients 
who suffered a cardiac arrest related to major trauma.
Data collection and outcome measures
We recorded the following information for each patient: 
age, gender, comorbidities (defined in Additional file  1: 
Table S1), variables derived from the Utstein template 
[15], critical interventions implemented at the time of 
cardiac arrest or after sustained ROSC, and the maxi-
mum and minimum BG levels measured during the 
24  h after sustained ROSC. For each patient, we calcu-
lated the mean BG level by averaging the maximum and 
minimum BG levels. Hyperglycaemia was defined as a 
BG level greater than 240  mg/dL (13.3  mmol/L); hypo-
glycaemia was defined as a BG level less than 70 mg/dL 
(3.9 mmol/L) [8].
The primary outcome was favourable neurological out-
come at hospital discharge, and the secondary outcome 
was survival to hospital discharge. Favourable neurologi-
cal outcome was defined as a score of 1 or 2 on the cer-
ebral performance category (CPC) scale [16]. The CPC 
scale [16] is a validated 5-point scale of neurological disa-
bility (1, good cerebral performance; 2, moderate cerebral 
disability; 3, severe cerebral disability; 4, coma/vegetative 
state; 5, death). Patients with a CPC score of 1 or 2 had 
sufficient cerebral function to live independently. We ret-
rospectively determined the CPC score for each patient 
by reviewing medical records.
Statistical analysis
We used R 2.15.3 software (R Foundation for Statisti-
cal Computing, Vienna, Austria) for data analysis. Cat-
egorical data are expressed as counts and proportions; 
continuous data are expressed as means and standard 
deviations. We compared categorical variables with the 
Fisher’s exact test, and we compared continuous variables 
with the Wilcoxon rank-sum test. A two-tailed p value of 
less than 0.05 was considered statistically significant.
We selected the odds ratio (OR) as the outcome meas-
ure and we performed multivariable logistic regres-
sion analyses to examine the associations between 
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independent variables and outcomes. Among all indica-
tors of BG control, we selected mean BG level for use in 
the regression analyses. We considered all available inde-
pendent variables in the regression model, regardless of 
whether they were significant by univariate analysis. We 
applied the stepwise variable selection procedure (with 
iterations between the forward and backward steps) to 
obtain the final regression model. Significance levels for 
entry and to stay were set at 0.15 to avoid exclusion of 
potential candidate variables. We calculated the final 
regression model by excluding individual variables with 
a p value greater than 0.05 until all regression coefficients 
were statistically significant.
We used generalized additive models (GAMs) [17] 
to examine the nonlinear effects of continuous vari-
ables and, if necessary, to identify the appropriate cut-off 
point(s) for dichotomizing a continuous variable during 
the variable selection procedure. We tested the interac-
tions between DM and mean BG level during the model-
fitting process. We assessed the goodness-of-fit of the 
fitted regression model using c-statistics, adjusted gen-
eralized R2, and the Hosmer–Lemeshow goodness-of-fit 
test.
Results
A total of 1537 adult patients received chest compres-
sions for at least 2 min between 2006 and 2014. Of these, 
we excluded 723 patients because they did not achieve 
sustained ROSC, 403 patients because they did not have 
any measurements of BG level, and 9 patients because 
they experienced trauma-related cardiac arrest. We 
enrolled the remaining 402 patients for further analysis. 
The results of comparison between patients with and 
without post-ROSC BG level were presented in Addi-
tional file 2: Tables S2 and Additional file 3: Table S3.
Tables  1 and 2 provide the features of cardiac arrest 
events before, during, and after CPR for all patients in 
the cohort. The mean age of the patients was 65.4 years. 
There were 157 patients (39.1 %) with DM. A total of 138 
cardiac arrest events (34.3 %) occurred in the ICUs and 
217 events (54.0 %) occurred on the general wards. The 
majority (82.3 %) of initial rhythms were non-shockable 
rhythms, including pulseless electrical activity and asys-
tole. The average CPR duration was 18.2 min. The aver-
age mean BG level was 209.9  mg/dL (11.7  mmol/L). 
In all, 199 patients (49.5 %) had at least one episode of 
hyperglycaemia and 55 patients (13.7 %) had at least one 
episode of hypoglycaemia. Only 130 patients (32.3  %) 
survived to hospital discharge; of these, 70 patients 
(17.4  %) demonstrated favourable neurological status. 
The characteristics and outcomes of patients stratified 
by DM are reported in Additional file  4: Tables S4 and 
Additional file 5: Table S5.
We placed all independent variables listed in Tables 1 
and 2, as well as the pre-specified interaction terms, in 
the regression analysis for variable selection. The GAM 
plot demonstrated the non-linear association between 
logit (p), where p represented the probability for clinical 
outcomes, including favourable neurological outcome 
and survival to hospital discharge (Additional file 6: Fig-
ures S1–S4) and mean BG level. If logit (p) was greater 
than zero, the odds for favourable clinical outcomes were 
greater than one. Therefore, the mean BG level was trans-
formed into a binary variable during the model-fitting 
process according to each identified optimal range of BG 
level.
Tables 3 and 4 provide the ORs of factors that signifi-
cantly correlated with clinical outcomes. For patients 
with DM, a mean BG level between 183 and 307 mg/dL 
(10.2–17.1  mmol/L) was significantly associated with 
favourable neurological outcome (OR 2.71, 95  % confi-
dence interval [CI] 1.18–6.20; p value = 0.02); a mean BG 
level between 141 and 317 mg/dL (8.2 and 17.6 mmol/L) 
was significantly associated with survival to hospital dis-
charge (OR 2.38, 95 % CI 1.26–4.53; p value = 0.008). For 
patients without DM, the identified optimal mean BG 
level between 142 and 250 mg/dL (7.9–13.9 mmol/L) was 
not significantly associated with favourable neurological 
outcome (OR 1.38, 95  % CI 0.67–2.86; p value =  0.38), 
but a mean BG level between 143 and 268 mg/dL (7.9–
14.9  mmol/L) was significantly associated with survival 




In this retrospective observational study, we found 
that post-ROSC BG level is associated with neurologi-
cal and survival outcomes for IHCA patients. The opti-
mal BG level for IHCA patients might differ according 
to the presence or absence of DM. Less stringent post-
ROSC glycaemic control than that recommended by the 
ERC (i.e., maintaining the BG level below 180 mg/dL or 
10 mmol/L [10] might be appropriate for some patients. 
Except BG level, other identified significant prognos-
tic factors of IHCA were consistent with those reported 
from previous studies [18].
Comparison with previous studies
In studies of OHCA outcomes, hyperglycaemia has been 
associated with poor neurological recovery [4–7]. For 
OHCA patients with ventricular fibrillation, Müllner 
et al. [4] and Nurmi et al. [5] indicated that elevated BG 
level in the early post-ROSC phase was associated with 
unfavourable neurological outcome. However, comor-
bidities were not considered in the statistical analyses of 
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either of these studies [4, 5]. Kaukonen et  al. [19] dem-
onstrated that hyperglycaemia in critically ill patients 
may simply be an indicator of illness severity and that 
the association between hyperglycaemia and mortal-
ity was attenuated when lactate levels were considered 
in the regression analyses. Furthermore, Steingrub et al. 
[20] indicated that an association between the early post-
ROSC BG level and neurologic outcome might not exist 
because a higher early post-ROSC BG level may only be 
an epiphenomenon of prolonged arrest duration, which 
itself would cause poor clinical outcomes. Without con-
sidering comorbidities and peri-CPR circumstances [4, 
5], the association between hyperglycaemia and neuro-
logical outcome might be biased.
For OHCA patients receiving therapeutic hypother-
mia, Kim et  al. [7] noted that elevated BG level in the 
early post-ROSC phase correlated with poor neurologi-
cal recovery. However, Losert et  al. [21] reported that 
moderate elevation of BG level at 12  h after ROSC was 
associated with favourable neurological outcome in non-
DM patients. For OHCA patients who survived longer 
than 48  h after ROSC, Daviaud et  al. [6] demonstrated 
that a high median BG level over this 48-h period was 
associated with poor neurological outcome. Neverthe-
less, the mode of death differs between OHCA and IHCA 
patients, with a higher proportion of patients dying from 
neurological disability in the former group [22]. The pro-
portion of IHCA patients receiving therapeutic hypother-
mia is also low [23]. Therefore, it is unclear whether the 
results of these OHCA studies [6, 7, 21] can be applied to 
IHCA patients.
Beiser et  al. [8] were the first to explore the associa-
tion between BG level and survival outcome for IHCA 
by analysing a representative nationwide database. They 
demonstrated that the patterns of association between 
BG level and survival outcome were different for DM 
and non-DM patients. Still, in the study by Beiser et  al. 
[8], maximum and minimum BG levels over the first 
24 h after ROSC were analysed separately in the regres-
sion analysis, making the results difficult to interpret 
and apply. Even if BG levels were the same, the survival 
odds differed depending on the category (i.e. minimum 
or maximum BG level) to which the value was ascribed, 
which could only be known retrospectively [8].
Interpretation of current analysis
We chose to use the mean BG level in our analysis 
to avoid the issue raised by Beiser et  al. [8] Our find-
ings indicate that the patterns of association between 
BG level and survival were similar to those reported by 
Beiser et al. [8], demonstrating reverse-U shaped curves 
(Additional file  6: Figures S3, S4) with lower survival 
Table 1 Baseline characteristics of study patients stratified by neurological outcome
a SD standard deviation
Variables All patients (n = 402) Patients with favourable neurolog-
ical outcome at hospital discharge 
(n = 70)
Patients without favourable 
neurological outcome at hospital 
discharge (n = 332)
p value
Age, y (SDa) 65.4 (15.7) 62.5 (14.0) 66.1 (16.0) 0.03
Male, n (%) 243 (60.4) 52 (74.3) 191 (57.5) 0.01
Comorbidities, n (%)
 Heart failure 109 (27.1) 25 (35.7) 84 (25.3) 0.08
 Myocardial infarction 60 (14.9) 19 (27.1) 41 (12.3) 0.003
 Arrhythmia 91 (22.6) 17 (24.3) 74 (22.3) 0.75
 Hypotension 111 (27.6) 17 (24.3) 94 (28.3) 0.56
 Respiratory insufficiency 272 (67.7) 40 (57.1) 232 (69.9) 0.05
 Renal insufficiency 179 (44.5) 22 (31.4) 157 (47.3) 0.02
 Hepatic insufficiency 71 (17.7) 7 (10) 64 (19.3) 0.08
 Metabolic or electrolyte  
abnormality
83 (20.6) 10 (14.3) 73 (22.0) 0.19
 Diabetes mellitus 157 (39.1) 31 (44.3) 126 (38.0) 0.35
 Baseline evidence of motor, cogni‑
tive, or functional deficits
177 (44.0) 23 (32.9) 154 (46.4) 0.05
 Acute stroke 22 (5.5) 2 (2.9) 20 (6.0) 0.39
 Favourable neurological status 24 h 
before cardiac arrest
215 (53.5) 50 (71.4) 165 (49.7) <0.001
 Bacteraemia 31 (7.7) 2 (2.9) 29 (8.7) 0.14
 Metastatic cancer or any blood 
borne malignancy
65 (16.2) 1 (1.4) 64 (19.3) <0.001
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odds for patients with hypoglycaemia or hyperglycae-
mia. Furthermore, for IHCA patients with DM, a BG 
level between 183 and 307  mg/dL (10.2–17.1  mmol/L) 
was significantly associated with favourable neurological 
outcome; for IHCA patients without DM, the association 
was not significant, which may be due to inadequate sta-
tistical power. Finally, our study demonstrated that the 
upper bounds of optimal BG levels for both neurologi-
cal and survival outcomes were higher in DM patients 
than in non-DM patients. This result corresponds to the 
findings of Egi et al. [14], who reported that critically ill 
DM patients were more capable of tolerating the influ-
ences of hyperglycaemia than patients without DM, and 
DM patients experienced significantly lower mortality at 
all levels of hyperglycaemia. Nevertheless, for both DM 
and non-DM patients, the upper limits of the optimal BG 
range were higher than the recommendations of the ERC 
[10].
The harm caused by hypoglycaemia in critically ill 
patients is well recognized [11, 12], but the influence 
Table 2 Features, interventions, and outcomes of cardiac arrest events stratified by neurological outcome
a CPR cardiopulmonary resuscitation
b SD standard deviation
c ROSC return of spontaneous circulation
Variables All patients (n = 402) Patients with favourable neurolog-
ical outcome at hospital discharge 
(n = 70)
Patients without favourable 
neurological outcome at hospital 
discharge (n = 332)
p value
Arrest at night, n (%) 240 (59.7) 41 (58.6) 199 (59.9) 0.89
Arrest on weekend, n (%) 110 (27.4) 17 (24.3) 93 (28.0) 0.56
Arrest location, n (%) 0.01
 Intensive care unit 138 (34.3) 30 (42.9) 108 (32.5)
 General ward 217 (54.0) 27 (38.6) 190 (57.2)
 Others 47 (11.7) 13 (18.6) 34 (10.2)
Witnessed arrest, n (%) 255 (63.4) 51 (72.9) 204 (61.4) 0.08
Monitored status, n (%) 231 (57.6) 49 (71.0) 182 (54.8) 0.01
Shockable rhythm, n (%) 71 (17.7) 28 (40) 43 (13.0) <0.001
Critical care interventions in place at time of arrest, n (%)
 Mechanical ventilation 72 (17.9) 10 (14.3) 62 (18.7) 0.49
 Antiarrhythmics 32 (8.0) 7 (10) 25 (7.5) 0.47
 Vasopressors 128 (31.8) 24 (34.3) 104 (31.3) 0.67
 Dialysis 29 (7.2) 3 (4.3) 26 (7.8) 0.45
 Pulmonary artery catheter 7 (1.7) 3 (4.3) 4 (1.2) 0.10
 Intra‑aortic balloon pumping 6 (1.5) 2 (2.9) 4 (1.2) 0.28
CPRa duration, min (SDb) 18.2 (16.0) 12.7 (10.2) 19.3 (16.7) <0.001
Vital signs during the first 24 h after sustained ROSCc
 Fever, n (%) 105 (26.1) 17 (24.3) 88 (26.5) 0.77
 Post‑ROSC hypotension, n (%) 40 (10.0) 1 (1.4) 39 (11.7) 0.007
Indicators of glucose control during the first 24 h after sustained ROSC
 Maximum glucose level, mg/dl (SD) 259.0 (117.4) 264.6 (112.3) 257.8 (118.5) 0.67
 Minimum glucose level, mg/dl (SD) 160.8 (93.6) 158.2 (60.4) 161.4 (99.2) 0.45
 Mean glucose level, mg/dl (SD) 209.9 (92.7) 211.4 (75.1) 209.6.8 (96.1) 0.59
 Hyperglycaemia, n (%) 199 (49.5) 36 (51.4) 163 (49.1) 0.79
 Hypoglycaemia, n (%) 55 (13.7) 0 (0) 55 (16.6) <0.001
Post‑ROSC interventions, n (%)
 Extracorporeal membrane oxygena‑
tion
40 (10.0) 10 (14.3) 30 (9.0) 0.19
 Therapeutic hypothermia 11 (2.7) 3 (4.3) 8 (2.4) 0.41
 Percutaneous coronary intervention 32 (8.0) 18 (25.7) 14 (4.2) <0.001
Survival for 24 h, n (%) 296 (73.6) 70 (100) 226 (68.1) <0.001
Survival to hospital discharge, n (%) 130 (32.3) 70 (100) 60 (18.1) <0.001
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of hyperglycaemia is more controversial. Because of 
the ease of application in statistical analysis and clini-
cal practice, we selected mean BG level for our analysis. 
Mean values are subject to influences of extreme values 
and may, therefore, contribute to the elevated optimal 
BG level ranges. In previous studies, mean [24], median 
[6], and maximum/minimum [8] BG levels over cer-
tain periods have been used in analyses. Whether a sin-
gle value of BG could be used to assess glucose control 
over time is unknown. Eslami et al. [25] documented 30 
different published methods to describe the quality of 
glucose control, and the various indicators of glucose 
control adopted in different studies [4–8, 20, 21, 24] 
might be the reason why the AHA [9] does not recom-
mend a specific target BG level for post-ROSC patients. 
Future study is warranted to establish the optimal indi-
cator to depict and analyse the dynamics and impacts of 
BG levels.
Table 3 Multiple logistic regression model with favourable neurological outcome at hospital discharge as the dependent 
variable
Goodness-of-fit assessment: n = 402, adjusted generalized R2 = 0.40, the estimated area under the receiver operating characteristic curve = 0.86, and the Hosmer and 
Lemeshow goodness-of-fit Chi Squared test p = 0.79
a The display of independent variables is arranged in order of these variables in Tables 1 and 2
b CPR cardiopulmonary resuscitation
c ROSC return of spontaneous circulation
Independent variablea Odds ratio 95 % confidence interval p value
Age between 30 and 70 years 2.32 1.21–4.59 0.01
Male 2.21 1.13–4.51 0.02
Renal insufficiency 0.45 0.23–0.86 0.02
DM * Mean glucose level between 183 and 307 mg/dl 2.71 1.18–6.20 0.02
Without DM * Mean glucose level between 142 and 250 mg/dl 1.38 0.67–2.86 0.38
Baseline evidence of motor, cognitive, or functional deficits 0.41 0.20–0.80 0.01
Favourable neurological status 24 h before cardiac arrest 3.76 1.88–7.85 <0.001
Metastatic cancer or any blood borne malignancy 0.05 0.003–0.26 0.005
Arrest on general ward 0.44 0.22–0.87 0.02
Shockable rhythm 2.84 1.37–5.88 0.005
CPRb duration 0.95 0.92–0.98 0.002
Post‑ROSCc percutaneous coronary intervention 2.76 1.09–7.02 0.03
Table 4 Multiple logistic regression model with survival to hospital discharge as the dependent variable
Goodness-of-fit assessment: n = 402, adjusted generalized R2 = 0.36, the estimated area under the receiver operating characteristic (ROC) curve = 0.82, and the 
Hosmer and Lemeshow goodness-of-fit Chi Squared test p = 0.69
a The display of independent variables is arranged by the order of these variables in Tables 1 and 2
b CPR cardiopulmonary resuscitation
c ROSC return of spontaneous circulation
Independent variablea Odds ratio 95 % confidence interval p value
Age 0.98 0.97–1.00 0.02
Hypotension 0.48 0.26–0.86 0.02
Renal insufficiency 0.59 0.35–0.98 0.04
Hepatic insufficiency 0.32 0.14–0.69 0.006
DM * Mean glucose level between 141 and 317 mg/dl 2.38 1.26–4.53 0.008
Without DM * Mean glucose level between 143 and 268 mg/dl 2.93 1.62–5.40 <0.001
Favourable neurological status 24 h before cardiac arrest 1.72 1.04–2.87 0.04
Metastatic cancer or any blood borne malignancy 0.23 0.09–0.53 <0.001
Shockable rhythm 2.70 1.48–5.00 0.001
CPRb duration 0.96 0.94–0.98 <0.001
Post‑ROSCc hypotension 0.07 0.004–0.36 0.01
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Protective role of moderate hyperglycaemia
Despite the limitation of using a single BG value to rep-
resent the dynamics of BG levels, the observed role of 
moderate hyperglycaemia in our study merits further 
discussion. Sustained hyperglycaemia could worsen sec-
ondary brain injury and lead to poor neurological out-
come [26, 27]. However, the definition of hyperglycaemia 
in terms of BG level has not been well established as it 
relates to brain injury. The human brain depends almost 
solely on the availability of systemic glucose supply to 
maintain normal metabolism. After ischemic insults, the 
transport of glucose to brain tissues may become inade-
quate to satisfy cerebral metabolism [28]. When cerebral 
perfusion is compromised, moderate hyperglycaemia 
may facilitate glucose transport through the elevated BG 
diffusion gradient that maximizes cellular glucose uptake 
[29]. Studies have shown that normalization of BG levels 
in critically ill patients with brain injury may be associ-
ated with greater risk of critical reductions in brain glu-
cose levels and energy crises [30, 31]. Therefore, acute 
stress hyperglycaemia noted during the early post-ROSC 
phase might be a physiologic, rather than a pathologic, 
response and attempts at interfering with this complex 
adaptive response may be harmful rather than protective 
[32].
Oksanen et al. [13] indicated that, for OHCA patients, 
a strict BG control strategy would lead to more severe 
brain injuries. In other critically ill patients, strict BG 
control has not been shown to reduce mortality, which 
was probably caused by an increased incidence of hypo-
glycaemia [33]. On the basis of our results, relaxing the 
upper limit of BG levels recommended by the ERC may 
be justified [10]. A randomized clinical trial targeting 
two or more BG levels for post-arrest patients would be 
needed to verify this assumption. Also, as recent stud-
ies [34–36] indicated, the outcomes of DM patients fol-
lowing cardiac arrest might be distinct from those of 
non-DM patients. Future studies should address the 
implication of DM in the pathogenesis of mortality and 
morbidity after cardiac arrest.
Study limitations
This study has several limitations that must be considered. 
First, this was an observational study, which can only 
establish an association, rather than a causal relationship, 
between independent and dependent variables. Second, 
the effects of unmeasured confounders might bias the 
results. Third, our study did not involve any specific pro-
tocol for BG control. We did not suggest that clinicians 
actively administer intravenous glucose to maintain the 
BG level at a certain range or that clinicians should allow 
permissive hyperglycaemia. Administration of intrave-
nous glucose might be associated with worse neurological 
outcome for post-ROSC patients [37]. The optimal strat-
egy to maintain BG within a certain range should be 
examined in a randomized controlled trial. Fourth, about 
half of patients who achieved sustained ROSC were 
excluded from our analysis because of lack of measure-
ments of BG level after sustained ROSC. As shown in the 
Additional file 2: Tables S2 and Additional file 3: Table S3, 
although there were no significant baseline differences 
between patients with and without measurements of BG 
levels, the outcomes of the former were better than the 
latter. Therefore, patients without any measurement of BG 
levels may have more unstable haemodynamics, leading 
to the absence of any BG levels measured after sustained 
ROSC. This kind of selection bias may only be resolved 
through a prospective study with a protocol for monitor-
ing post-ROSC BG levels. Finally, this was a single-centre 
study, which might limit the generalizability of the study 
conclusion. Since the guideline-based care varied signifi-
cantly across hospitals [38], a multi-centre study would be 
needed to confirm our observation.
Conclusions
The mean BG level over the first 24 h after ROSC is asso-
ciated with neurological outcomes of IHCA patients with 
DM. For neurological and survival outcomes, the optimal 
BG range may be higher for patients with DM than for 
patients without DM.
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